BillionToOne, Inc.
BLLN Healthcare Diagnostics & Research
BillionToOne, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $305.1 million, up 100.0% from fiscal 2024.
- Revenue
- +47.2%
- EPS
- +164.3%
- Free cash flow
- +9.25%
- Total debt
- +60.6%
Quarter to September 2026, against a year earlier
Follow BLLN
Alert me
BillionToOne, Inc. (BLLN) EV/FCF
As of 5 November 2026, BillionToOne, Inc. (BLLN) trades at a EV/FCF of 142×. Over the past ten years it has ranged from −302× (November 2025) to 196× (August 2026); the current reading is higher than 75% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 54.8× | — |
| FY2024 | −247× | — |
| FY2023 | −247× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 134× | (12.70%) |
| Jun 2026 | 154× | 27.91% |
| Mar 2026 | 120× | 119.84% |
| Dec 2025 | 54.8× | — |
| 4 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| ADPT Adaptive Biotechnologies Corporation compare | −494× |
| NEO NeoGenomics, Inc. compare | −96.9× |
| GRAL GRAIL, Inc. compare | −15.9× |
| VCYT Veracyte, Inc. compare | 9.0× |
| QGEN QIAGEN N.V. compare | 25.8× |
| SHC Sotera Health Company compare | 47.0× |
| CDNA CareDx, Inc. compare | 64.7× |
| BLLN BillionToOne, Inc. | 142× |
| RDNT RadNet, Inc. compare | 208× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on BLLN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Shares outstanding
- Book value per share
- The full statement